Δημοσιεύσεις
Δημοσιεύσεις
Gountas, Ilias; Sypsa, Vana; Papatheodoridis, George; Souliotis, Kyriakos; Athanasakis, Kostas; Razavi, Homie; Hatzakis, Angelos
Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals Journal Article
In: World J Gastroenterol, vol. 25, no. 11, pp. 1327–1340, 2019.
Abstract | BibTeX | Ετικέτες: Awareness and screening programs; Cost effectiveness; Cost of elimination; Hepatitis C elimination; Indirect costs; Mathematical modelling; Projections; World Health Organization targets
@article{Gountas2019-ee,
title = {Economic evaluation of the hepatitis C elimination strategy in
Greece in the era of affordable direct-acting antivirals},
author = {Ilias Gountas and Vana Sypsa and George Papatheodoridis and Kyriakos Souliotis and Kostas Athanasakis and Homie Razavi and Angelos Hatzakis},
year = {2019},
date = {2019-03-01},
journal = {World J Gastroenterol},
volume = {25},
number = {11},
pages = {1327--1340},
abstract = {BACKGROUND: Hepatitis C virus (HCV) is a leading cause of
worldwide liver-related morbidity and mortality. The World Health
Organization released an integrated strategy targeting
HCV-elimination by 2030. This study aims to estimate the required
interventions to achieve elimination using updated information
for direct-acting antiviral (DAA) treatment coverage, to compute
the total costs (including indirect/societal costs) of the
strategy and to identify whether the elimination strategy is
cost-effective/cost-saving in Greece. AIM: To estimate the
required interventions and subsequent costs to achieve HCV
elimination in Greece. METHODS: A previously validated
mathematical model was adapted to the Greek HCV-infected
population to compare the outcomes of DAA treatment without the
additional implementation of awareness or screening campaigns
versus an HCV elimination strategy, which includes a sufficient
number of treated patients. We estimated the total costs (direct
and indirect costs), the disability-adjusted life years and the
incremental cost-effectiveness ratio using two different price
scenarios. RESULTS: Without the implementation of awareness or
screening campaigns, approximately 20000 patients would be
diagnosed and treated with DAAs by 2030. This strategy would
result in a 19.6% increase in HCV-related mortality in 2030
compared to 2015. To achieve the elimination goal, 90000 patients
need to be treated by 2030. Under the elimination scenario,
viremic cases would decrease by 78.8% in 2030 compared to 2015.
The cumulative direct costs to eliminate the disease would range
from 2.1-2.3 billion euros (€) by 2030, while the indirect costs
would be €1.1 billion. The total elimination cost in Greece would
range from €3.2-3.4 billion by 2030. The cost per averted
disability-adjusted life year is estimated between €10100 and
€13380, indicating that the elimination strategy is very
cost-effective. Furthermore, HCV elimination strategy would save
€560-895 million by 2035. CONCLUSION: Without large screening
programs, elimination of HCV cannot be achieved. The HCV
elimination strategy is feasible and cost-saving despite the
uncertainty of the future cost of DAAs in Greece.},
keywords = {Awareness and screening programs; Cost effectiveness; Cost of elimination; Hepatitis C elimination; Indirect costs; Mathematical modelling; Projections; World Health Organization targets},
pubstate = {published},
tppubtype = {article}
}